Researchers at the University of Oklahoma have developed a breakthrough method of adding a single nitrogen atom to molecules, ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash., Jan. 08, ...

AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public.